Birgit Linkohr, Margit Heier, Christian Gieger, Barbara Thorand, Harald Grallert, Rolf Holle, Stefan Karrasch, Wolfgang Koenig, Karl-Heinz Ladwig, Michael Laxy, Bettina Lorenz-Depiereux, Susanne Rospleszcz, Alexandra Schneider, Holger Schulz, Lars Schwettmann, Marie Standl, Melanie Waldenberger, Rui Wang-Sattler, Kathrin Wolf, Marco Dallavalle, Ina-Maria Rückert-Eheberg, Andrea Schneider, Reiner Leidl, Heinz-Erich Wichmann, Annette Peters
{"title":"Cohort Profile: Cooperative Health Research in the Region of Augsburg (KORA) 1984-2024.","authors":"Birgit Linkohr, Margit Heier, Christian Gieger, Barbara Thorand, Harald Grallert, Rolf Holle, Stefan Karrasch, Wolfgang Koenig, Karl-Heinz Ladwig, Michael Laxy, Bettina Lorenz-Depiereux, Susanne Rospleszcz, Alexandra Schneider, Holger Schulz, Lars Schwettmann, Marie Standl, Melanie Waldenberger, Rui Wang-Sattler, Kathrin Wolf, Marco Dallavalle, Ina-Maria Rückert-Eheberg, Andrea Schneider, Reiner Leidl, Heinz-Erich Wichmann, Annette Peters","doi":"10.1093/ije/dyaf187","DOIUrl":"10.1093/ije/dyaf187","url":null,"abstract":"","PeriodicalId":14147,"journal":{"name":"International journal of epidemiology","volume":"54 6","pages":""},"PeriodicalIF":5.9,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12597660/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145482031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Senjuti Saha, Naito Kanon, Mohammad Shahidul Islam, Mohammad Shameem Hassan, Yogesh Hooda, Lubana Tanvia, Qazi Sadeq-Ur Rahman, Rajib C Das, Shampa Saha, Sanwarul Bari, A K M Tanvir Hossain, Md Shariful Islam, Gary L Darmstadt, Shams E L Arifeen, Samir K Saha
{"title":"Cohort Profile: Health and Demographic Surveillance System in Mirzapur, Tangail, Bangladesh.","authors":"Senjuti Saha, Naito Kanon, Mohammad Shahidul Islam, Mohammad Shameem Hassan, Yogesh Hooda, Lubana Tanvia, Qazi Sadeq-Ur Rahman, Rajib C Das, Shampa Saha, Sanwarul Bari, A K M Tanvir Hossain, Md Shariful Islam, Gary L Darmstadt, Shams E L Arifeen, Samir K Saha","doi":"10.1093/ije/dyaf184","DOIUrl":"https://doi.org/10.1093/ije/dyaf184","url":null,"abstract":"","PeriodicalId":14147,"journal":{"name":"International journal of epidemiology","volume":"54 6","pages":""},"PeriodicalIF":5.9,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145482008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sylvana Côté, Catherine Haeck, Marc Dorais, Gillis-Delmas Tchouangue-Dinkou, Mike Benigeri, Nadia Roumeliotis
{"title":"Data Resource Profile: The Enfants du Québec dataset.","authors":"Sylvana Côté, Catherine Haeck, Marc Dorais, Gillis-Delmas Tchouangue-Dinkou, Mike Benigeri, Nadia Roumeliotis","doi":"10.1093/ije/dyaf195","DOIUrl":"https://doi.org/10.1093/ije/dyaf195","url":null,"abstract":"","PeriodicalId":14147,"journal":{"name":"International journal of epidemiology","volume":"54 6","pages":""},"PeriodicalIF":5.9,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145581907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Everlyn Kamau, Pearl Anne Ante-Testard, Julianna Colado, Scott D Nash, Diana L Martin, Benjamin F Arnold
{"title":"Data Resource Profile: Global Trachoma Serology Data Repository.","authors":"Everlyn Kamau, Pearl Anne Ante-Testard, Julianna Colado, Scott D Nash, Diana L Martin, Benjamin F Arnold","doi":"10.1093/ije/dyaf183","DOIUrl":"10.1093/ije/dyaf183","url":null,"abstract":"","PeriodicalId":14147,"journal":{"name":"International journal of epidemiology","volume":"54 6","pages":""},"PeriodicalIF":5.9,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12597674/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145482013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yingxiao Yan, Anton Ribbenstedt, Tessa Schillemans, Carl Brunius
{"title":"Software Application Profile: TriplotGUI, a molecular epidemiology toolbox for investigating associations between exposures, omics, and outcomes.","authors":"Yingxiao Yan, Anton Ribbenstedt, Tessa Schillemans, Carl Brunius","doi":"10.1093/ije/dyaf203","DOIUrl":"10.1093/ije/dyaf203","url":null,"abstract":"","PeriodicalId":14147,"journal":{"name":"International journal of epidemiology","volume":"54 6","pages":""},"PeriodicalIF":5.9,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12677948/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145677399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mika Ala-Korpela, Siyu Zhao, Corey Giles, Kevin Huynh, Johannes Kettunen, Peter J Meikle, Ville-Petteri Mäkinen
{"title":"Interpretation of lipidomics associations with type 2 diabetes: the importance of lipoprotein mediation.","authors":"Mika Ala-Korpela, Siyu Zhao, Corey Giles, Kevin Huynh, Johannes Kettunen, Peter J Meikle, Ville-Petteri Mäkinen","doi":"10.1093/ije/dyaf202","DOIUrl":"https://doi.org/10.1093/ije/dyaf202","url":null,"abstract":"","PeriodicalId":14147,"journal":{"name":"International journal of epidemiology","volume":"54 6","pages":""},"PeriodicalIF":5.9,"publicationDate":"2025-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145587301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Christina Bisgaard Jensen, Kristoffer Torp Hansen, Bodil Hammer Bech, Stefan Nygaard Hansen, Henrik Nielsen, Charlotte Ulrikka Rask, Per Fink, Thomas Meinertz Dantoft, Torben Jørgensen, Jeremy A Labrecque, Sanne Møller Thysen, Dorte Rytter
Background Post-acute non-specific symptoms such as headaches, muscular pain, and fatigue are frequently reported following COVID-19 vaccination, raising concerns about adverse events. As vaccine-hesitant individuals may be more likely to experience symptoms of vaccines, this study investigates whether COVID-19 vaccination increases the odds of post-acute non-specific symptoms, stratified by COVID-19 vaccine hesitancy. Methods This longitudinal study uses repeated measurements from the BiCoVac cohort—a random sample of 913 116 Danish citizens aged 16–65 years. Data were collected through national registers and questionnaires (May 2021–June 2022). Non-specific symptoms were identified by using the 25-item Bodily Distress Syndrome checklist and analysed by using logistic and linear regression models comparing vaccinated and unvaccinated individuals. Models were fitted with robust standard errors and inverse probability of selection weights. Results A total of 132 776 observations were collected from 61 316 COVID-19 vaccine-unconcerned individuals, 52 325 observations from 25 272 COVID-19 vaccine-sceptical individuals, and 10 242 observations from 5064 COVID-19 vaccine-concerned individuals. Among the vaccine-unconcerned individuals, those vaccinated had lower odds of most symptoms compared with unvaccinated individuals >4 weeks post-vaccination [e.g. muscular pain: odds ratio (OR) = 0.56, 95% confidence interval (CI): 0.47–0.68]. A similar tendency was found for vaccine-sceptical individuals, although with attenuated estimates. Conversely, among vaccine-concerned individuals, we observed a tendency for higher odds of most symptoms >4 weeks post-vaccination compared with unvaccinated individuals (e.g. muscular pain: OR = 1.23, 95% CI: 0.91–1.67). Conclusion For most individuals aged 16–65 years, we found no evidence of post-acute symptoms after COVID-19 vaccination. Vaccinated vaccine-concerned individuals were, however, more likely to report most symptoms, potentially due to reporting bias or nocebo effects.
{"title":"Post-acute non-specific symptoms following COVID-19 vaccination: a Danish population-based study","authors":"Christina Bisgaard Jensen, Kristoffer Torp Hansen, Bodil Hammer Bech, Stefan Nygaard Hansen, Henrik Nielsen, Charlotte Ulrikka Rask, Per Fink, Thomas Meinertz Dantoft, Torben Jørgensen, Jeremy A Labrecque, Sanne Møller Thysen, Dorte Rytter","doi":"10.1093/ije/dyaf173","DOIUrl":"https://doi.org/10.1093/ije/dyaf173","url":null,"abstract":"Background Post-acute non-specific symptoms such as headaches, muscular pain, and fatigue are frequently reported following COVID-19 vaccination, raising concerns about adverse events. As vaccine-hesitant individuals may be more likely to experience symptoms of vaccines, this study investigates whether COVID-19 vaccination increases the odds of post-acute non-specific symptoms, stratified by COVID-19 vaccine hesitancy. Methods This longitudinal study uses repeated measurements from the BiCoVac cohort—a random sample of 913 116 Danish citizens aged 16–65 years. Data were collected through national registers and questionnaires (May 2021–June 2022). Non-specific symptoms were identified by using the 25-item Bodily Distress Syndrome checklist and analysed by using logistic and linear regression models comparing vaccinated and unvaccinated individuals. Models were fitted with robust standard errors and inverse probability of selection weights. Results A total of 132 776 observations were collected from 61 316 COVID-19 vaccine-unconcerned individuals, 52 325 observations from 25 272 COVID-19 vaccine-sceptical individuals, and 10 242 observations from 5064 COVID-19 vaccine-concerned individuals. Among the vaccine-unconcerned individuals, those vaccinated had lower odds of most symptoms compared with unvaccinated individuals >4 weeks post-vaccination [e.g. muscular pain: odds ratio (OR) = 0.56, 95% confidence interval (CI): 0.47–0.68]. A similar tendency was found for vaccine-sceptical individuals, although with attenuated estimates. Conversely, among vaccine-concerned individuals, we observed a tendency for higher odds of most symptoms >4 weeks post-vaccination compared with unvaccinated individuals (e.g. muscular pain: OR = 1.23, 95% CI: 0.91–1.67). Conclusion For most individuals aged 16–65 years, we found no evidence of post-acute symptoms after COVID-19 vaccination. Vaccinated vaccine-concerned individuals were, however, more likely to report most symptoms, potentially due to reporting bias or nocebo effects.","PeriodicalId":14147,"journal":{"name":"International journal of epidemiology","volume":"110 1","pages":""},"PeriodicalIF":7.7,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145260663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background Although some studies suggest an increased risk of shingles following coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, no research has examined this relationship in real-world clinical settings. We aimed to investigate the association between shingles and COVID-19 by using a Japanese inpatient and outpatient claims database. Methods We identified patients with COVID-19 from 1 January 2020 to 30 January 2023 by using a Japanese inpatient and outpatient claims database. We also identified those who developed shingles and received antiviral drugs within 90 days before or after their COVID-19 diagnosis. Using self-controlled case series methods, we evaluated the relationship between shingles and COVID-19. We calculated the incidence rate ratio (IRR) [95% confidence interval (CI)] for shingles during the buffer period (days –35 to –7), pre-exposure period (days –6 to 0), and risk periods of the first and second, third and fourth, and fifth and sixth weeks following COVID-19 infection compared with a control period outside these intervals. Results Among 399 381 patients with COVID-19, 558 were diagnosed with shingles. The IRR was significantly elevated during the first and second (5.1, 95% CI 3.9–6.6), third and fourth (1.7, 95% CI 1.2–2.5), and fifth and sixth weeks (1.5, 95% CI 1.0–2.3) compared with a control period. Conclusion This study of a Japanese inpatient and outpatient database reveals a relationship between shingles and COVID-19, indicating that shingles may be a characteristic of the virus and highlighting the need for varicella-zoster vaccination alongside SARS-CoV-2 in the COVID-19 era.
虽然一些研究表明，由严重急性呼吸综合征冠状病毒2 （SARS-CoV-2）感染引起的2019冠状病毒病（COVID-19）后带状疱疹的风险增加，但没有研究在现实世界的临床环境中检验这种关系。我们的目的是通过使用日本住院和门诊索赔数据库来调查带状疱疹和COVID-19之间的关系。方法利用日本住院和门诊索赔数据库，对2020年1月1日至2023年1月30日期间的COVID-19患者进行鉴定。我们还确定了那些在COVID-19诊断前后90天内患带状疱疹并接受抗病毒药物治疗的患者。采用自我控制病例系列方法，我们评估了带状疱疹与COVID-19之间的关系。我们计算了缓冲期（-35天至-7天）、暴露前期（-6天至0天）以及COVID-19感染后第一、第二、第三、第四、第五和第六周的危险期与这些间隔之外的对照期的带状疱疹发病率比（IRR）[95%置信区间（CI）]。结果399 381例新冠肺炎患者中，带状疱疹确诊558例。与对照期相比，IRR在第一和第二周（5.1,95% CI 3.9-6.6）、第三和第四周（1.7,95% CI 1.2-2.5）和第五和第六周（1.5,95% CI 1.0-2.3）显著升高。结论对日本住院和门诊患者数据库的研究揭示了带状疱疹与COVID-19之间的关系，表明带状疱疹可能是该病毒的一个特征，并强调在COVID-19时代需要在接种SARS-CoV-2的同时接种水痘-带状疱疹疫苗。
{"title":"Relationship between shingles and coronavirus disease 2019: a self-controlled case series study","authors":"Tomoki Mizuno, Jun Suzuki, Shota Takahashi, Haruka Imai, Hideya Itagaki, Tomohiro Akaba, Makiko Yoshida, Shiro Endo","doi":"10.1093/ije/dyaf162","DOIUrl":"https://doi.org/10.1093/ije/dyaf162","url":null,"abstract":"Background Although some studies suggest an increased risk of shingles following coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, no research has examined this relationship in real-world clinical settings. We aimed to investigate the association between shingles and COVID-19 by using a Japanese inpatient and outpatient claims database. Methods We identified patients with COVID-19 from 1 January 2020 to 30 January 2023 by using a Japanese inpatient and outpatient claims database. We also identified those who developed shingles and received antiviral drugs within 90 days before or after their COVID-19 diagnosis. Using self-controlled case series methods, we evaluated the relationship between shingles and COVID-19. We calculated the incidence rate ratio (IRR) [95% confidence interval (CI)] for shingles during the buffer period (days –35 to –7), pre-exposure period (days –6 to 0), and risk periods of the first and second, third and fourth, and fifth and sixth weeks following COVID-19 infection compared with a control period outside these intervals. Results Among 399 381 patients with COVID-19, 558 were diagnosed with shingles. The IRR was significantly elevated during the first and second (5.1, 95% CI 3.9–6.6), third and fourth (1.7, 95% CI 1.2–2.5), and fifth and sixth weeks (1.5, 95% CI 1.0–2.3) compared with a control period. Conclusion This study of a Japanese inpatient and outpatient database reveals a relationship between shingles and COVID-19, indicating that shingles may be a characteristic of the virus and highlighting the need for varicella-zoster vaccination alongside SARS-CoV-2 in the COVID-19 era.","PeriodicalId":14147,"journal":{"name":"International journal of epidemiology","volume":"2 1","pages":""},"PeriodicalIF":7.7,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145154123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Isobel L Ward, Charlotte R Bermingham, Kate Soldan, Vahé Nafilyan
Background In England, the national human papillomavirus (HPV) immunization programme was introduced in 2008 to prevent cervical cancer. Girls aged 12–13 years were offered routine vaccination and those aged 14–18 years in 2008 were offered ‘catch-up’ vaccination. We evaluate the effect of the HPV catch-up vaccination programmes on cervical cancer and cervical dysplasia diagnoses, and provide an estimate of the vaccine effectiveness. Methods Using the 2011 Census, Hospital Episode Statistics, and mortality data for the population of England, we exploit the cut-off in eligibility and apply a regression discontinuity design to assess the impact of HPV vaccination on cervical disease. Results Vaccination reduced the incidence of cervical dysplasia and cancer diagnoses by 31% and 75%, respectively, at ages 23–30 years in girls offered catch-up vaccination at ages 17–18 years compared with those who were just above the eligibility age for the catch-up vaccination, with a clear discontinuity. Reductions continued amongst girls offered routine vaccination. Conclusion These estimates, obtained by using a quasi-experimental approach, are similar to vaccine effectiveness estimates based on more traditional approaches. This approach provides further evidence of the HPV vaccination programme reducing adverse cervical outcomes in young women and could be used for future studies to evaluate major changes in HPV vaccination policy and for studies of longer-term outcomes including other cancers and deaths.
{"title":"Evaluating the effectiveness of the human papillomavirus vaccination programme in England, using a regression discontinuity design","authors":"Isobel L Ward, Charlotte R Bermingham, Kate Soldan, Vahé Nafilyan","doi":"10.1093/ije/dyaf156","DOIUrl":"https://doi.org/10.1093/ije/dyaf156","url":null,"abstract":"Background In England, the national human papillomavirus (HPV) immunization programme was introduced in 2008 to prevent cervical cancer. Girls aged 12–13 years were offered routine vaccination and those aged 14–18 years in 2008 were offered ‘catch-up’ vaccination. We evaluate the effect of the HPV catch-up vaccination programmes on cervical cancer and cervical dysplasia diagnoses, and provide an estimate of the vaccine effectiveness. Methods Using the 2011 Census, Hospital Episode Statistics, and mortality data for the population of England, we exploit the cut-off in eligibility and apply a regression discontinuity design to assess the impact of HPV vaccination on cervical disease. Results Vaccination reduced the incidence of cervical dysplasia and cancer diagnoses by 31% and 75%, respectively, at ages 23–30 years in girls offered catch-up vaccination at ages 17–18 years compared with those who were just above the eligibility age for the catch-up vaccination, with a clear discontinuity. Reductions continued amongst girls offered routine vaccination. Conclusion These estimates, obtained by using a quasi-experimental approach, are similar to vaccine effectiveness estimates based on more traditional approaches. This approach provides further evidence of the HPV vaccination programme reducing adverse cervical outcomes in young women and could be used for future studies to evaluate major changes in HPV vaccination policy and for studies of longer-term outcomes including other cancers and deaths.","PeriodicalId":14147,"journal":{"name":"International journal of epidemiology","volume":"2 1","pages":""},"PeriodicalIF":7.7,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145127772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：